Bivision, a biopharma company focusing on the development of visual targeted radionuclide therapy which integrates diagnosis with treatment, will continue to develop innovative targeted radionuclide drugs with the fresh proceeds.
Bivision (Chinese: 晶核生物) announced its completion of an Angel financing round worth nearly CNY 100 million recently. The round was led by Gaorong Capital (Chinese: 高榕资本), with the participation from IV Ventures, Lichen Capital (Chinese: 骊宸资本) and the existing investor Kaitai Capital (Chinese: 凯泰资本).
This funding will be used to accelerate the advancement of several innovative targeted radionuclide drugs to the clinical stage, and to upgrade its nuclear drug development platform.
Founded in 2021, the company strives to be a national leader in TRT in China through innovation and collaboration, with the goal of benefiting patients with cancer and other serious diseases worldwide. Supported by three technology platforms of targeted ligand screening, radiopharmaceutical conjugation, and clinical translation, Bivision's drug pipelines are progressing rapidly in parallel.
The company's competitors include C-Ray Therapeutics (Chinese: 通瑞生物), Hexin Medical (Chinese: 核欣医药) and Smart Nuclide (Chinese: 智核生物).